KTTA - A New BioTech Research Race Is Focused On Improving Life For MS Patients
(NewsDirect)
Learn Moreabout Pasithea Therapeutics by gaining access to the latest researchreport
Whenthe world is focused on a global pandemic no one saw coming four yearsago, the attention given to escalating diseases with no known cure canbe hidden from the public consciousness.
This is perhaps the case with multiplesclerosis (MS), an immune-mediated disease affecting the centralnervous system, which according to the National Institutes of Health,continues to grow.
The estimatednumber of people with MS worldwide increased from ~2.1 millionin 2013 to 2.8 million in 2020, with the global prevalence at almost36 per 100,000 people.
The increasednumber of cases has subsequently increased the demand for effectivediagnosis and treatment of multiple sclerosis. A recent FortuneBusiness Insights report said the global multiple sclerosisdrugs market size was valued at $23.68 billion in 2021 and isprojected to grow to $33.17 billion by 2029.
Rising MS NumbersSpur Increased Research
As companies launch new products and research, governmentinitiatives are projected to improve the accessibility of care andtreatment. The rising MS numbers are believed to be the primarycatalyst in market expansion. Active biotech companies in the MSmarket today include Pasithea Therapeutics Corp. (NASDAQ: KTTA ), BioNTech SE (NASDAQ: BNTX )and SIGA Technologies Inc . (NASDAQ: SIGA )and Moderna Inc. (NASDAQ: MRNA), among others.
Some are finding newresearch showing that an mRNA vaccine might also work in multiplesclerosis (MS). BioNTech and scientists at the Johannes GutenbergUniversity of Mainz hypothesized that an mRNA vaccine could work in atargeted fashion to help the immune system tolerate specificMS-related proteins without compromising normal immune function.
The BioNTech team developed an mRNAcandidate wrapping the genetic information coding for MS-causingself-antigens in fatty substances. A similar lipid nanoparticle isused in Comirnaty to protect the COVID-19 mRNA material until itreaches target cells, where it produces the antigen protein. Theresults were published in the journal Science .
PasitheaReports Progress In Pursuit Of MS Vaccine Development
Pasithea , a biotechnology company focused on discovering, researching anddeveloping new and effective treatments for psychiatric andneurological disorders, recently announced positive results from apreliminary preclinical proof-of-concept study of PAS002, itstolerizing vaccine program in MS.
The Pasithea vaccine promotes immune tolerance to aspecific myelin protein, reducing the severity of relapses and helpingthe test animals gain weight, indicating a better overall healthstatus.
“Although early-stage data, we’re thrilled with the resultsof this study and the strong preclinical efficacy data of ourtolerizing approach,” Pasithea CEO Dr. Tiago Reis Marquessaid.
Whileregular vaccines usually are designed to train the body to develop animmune response against a particular pathogen, tolerizing vaccinesessentially do the opposite, acting as a “reverse vaccine.” Thosevaccines train the immune system to tolerate a molecule, suppressingan unwanted immune response against it.
Pasithea hopes that helping the immune systemaccept GlialCAM, PAS002 will prevent the attacks that cause myelinloss in the brain and spinal cord, thereby reducing disease severityand MS relapses.
Another recent articlein Science showed published research that scientists have discovered about therisk of an individual contracting MS. The study showed that MSincreases 32-fold after a person is infected with the Epstein-Barrvirus. However, the risk of developing the condition does not increasewhen other viruses infect the patient. The scientists also tested MSbiomarkers showing neurodegeneration.
There are currently 15 vaccines activelyunder development for the Epstein-Barr virus, most of which are indiscovery or preclinical stages. The Modified vaccinia Ankara (MVA)vaccine under development by the Chinese University of Hong Kong is inPhase II. It uses the same technology as AstraZeneca plc (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ) on theirCOVID-19 vaccines.
The most prominent company involved, Moderna, has startedtesting the vaccine mRNA-1189, which uses mRNA technology, in Phase Istudies. If successful, the vaccine could be one of the first on themarket for the Epstein-Barr virus. Though the Moderna vaccinedoes not indicate MS, it could eventually help with diseaseprevention.
For more information onPasithea Technologies, visit pasithea.com .
Pasithea Therapeutics Corporation is a biotechnology companyfocused on the discovery, research and development of new andeffective treatments for central nervous system (CNS) disorders. Withan experienced team of experts in the fields of neuroscience andpsychopharmacology, Pasithea is developing new molecular entities forthe treatment of psychiatric and neurological disorders, includingAmyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS).Pasithea addresses the needs of patients currently suffering withmental illness by providing access to IV ketamine infusions both inclinics and in-home settings.
This post contains sponsoredadvertising content. This content is for informational purposes onlyand is not intended to be investing advice.
ContactDetails
TraDigital IR- Camille Baptiste
CompanyWebsite
Copyright (c) 2022 TheNewswire - All rights reserved.